Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D. Kobold S, et al. Among authors: haag f. Clin Dev Immunol. 2011;2011:302145. doi: 10.1155/2011/302145. Epub 2011 Nov 15. Clin Dev Immunol. 2011. PMID: 22190969 Free PMC article.
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D. Luetkens T, et al. Among authors: haag f. Cancer Immunol Immunother. 2014 Nov;63(11):1151-62. doi: 10.1007/s00262-014-1588-x. Epub 2014 Jul 31. Cancer Immunol Immunother. 2014. PMID: 25078248 Free PMC article.
A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma.
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M. Schieferdecker A, et al. Among authors: haag f. Blood. 2016 Jun 23;127(25):3202-14. doi: 10.1182/blood-2015-10-676536. Epub 2016 Mar 31. Blood. 2016. PMID: 27034429 Free article.
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F. Schütze K, et al. Among authors: haag f. Front Immunol. 2018 Nov 19;9:2553. doi: 10.3389/fimmu.2018.02553. eCollection 2018. Front Immunol. 2018. PMID: 30524421 Free PMC article.
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. Schriewer L, et al. Among authors: haag f. Theranostics. 2020 Feb 3;10(6):2645-2658. doi: 10.7150/thno.38533. eCollection 2020. Theranostics. 2020. PMID: 32194826 Free PMC article.
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar PH, Tsoka S, Bullinger L, Seubert E, Smit DJ, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W. Brauneck F, et al. Among authors: haag f. J Immunother Cancer. 2022 Dec;10(12):e004794. doi: 10.1136/jitc-2022-004794. J Immunother Cancer. 2022. PMID: 36549780 Free PMC article.
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro.
Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J. Brauneck F, et al. Among authors: haag f. Front Immunol. 2023 Oct 2;14:1250258. doi: 10.3389/fimmu.2023.1250258. eCollection 2023. Front Immunol. 2023. PMID: 37876933 Free PMC article.
267 results